Replication Data for: Efetividade do Trastuzumabe adjuvante em mulheres com câncer de mama HER-2+ no SUS
收藏官方服务：
资源简介：
Banco de dados do artigo.
应用场景：
创建时间：
2023-01-02
相关数据集
The use and impact of trastuzumab (Herceptin) for early and late stage HER-2 positive breast cancer in Australia
This project was established to conduct a long-term evaluation of the way in which trastuzumab (Herceptin) is used to treat early and late stage breast cancer in the real world clinical setting. Secon
DataCite Commons2022-07-26 更新80
Trastuzumab beyond progression in HER2-positive metastatic breast cancer
The data about continuing trastuzumab treatment beyond progression in HER2-positive breast cancer are lacking in Iraq. This study aimed for investigating the use of trastuzumab in Iraqi women with met
NIAID Data Ecosystem20
Dataset from A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuz
NIAID Data Ecosystem00
The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time
Dataset for the paper "The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time", DOI: 10.3332/ecancer.2022.1347
NIAID Data Ecosystem60
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
Please note, this study is only available to request by PALLAS investigators. This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the additi
DataCite Commons2025-06-01 更新00
